Nilofabicin

Synonym(s): CG-400549  |  CG549

Class: Fatty acid synthesis inhibitor (FabI inhibitor)

Spectrum of activity:	Gram-positive
Details of activity:	Inhibits FabI, which determines the completing of each cycle of elongation in the fatty acid synthesis. Active against Staphylococcus only.
Institute where first reported:	CrystalGenomics, South Korea
Year first mentioned:	2006
Highest developmental phase:	Phase 2 (NCT01593761)
Development status:	Active

Chemical structure(s):
Canonical SMILES:	CC1=C(C=CC=C1CN2C=CC(=CC2=O)OCCC3=CC=CS3)N
Isomeric SMILES:	CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3
InChI:	InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
InChI Key:	YCLREGRRHGLOAK-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/11844916

External links:
Guide to Pharmacology:	CG-400549
Main Source:	http://www.crystalgenomics.com/en/m21_3.php?subPipeCate=2#main
Citations:	https://www.ncbi.nlm.nih.gov/pubmed/17875997 http://www.ncbi.nlm.nih.gov/pubmed/24739388